EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine
carcinosarcoma with evidence of recurrence or progression.
The study aims to determine the activity of eribulin as a single agent and the combination of
eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks.
Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein
expression is a good functional biomarker to predict response to eribulin and pembrolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Australia New Zealand Gynaecological Oncology Group